

Is inhibitor eradication still a must?

Grifols EAHAD 2019 Satellite Symposium

Wednesday, February 6th
17:15 - 18:30, South Hall



12th ANNUAL CONGRESS
OF THE EUROPEAN ASSOCIATION
FOR HAEMOPHILIA AND ALLIED DISORDERS

Chairman: Manuel Carcao

The benefits of inhibitor eradication

M. Carcao (*Canada*)

Choosing the optimal concentrate for a successful ITI:

Basic and clinical evidence

M. Colucci (*Italy*)

V. Jiménez-Yuste (*Spain*)

The concomitant use of emicizumab and FVIII:

Basic and clinical evidence

I. Bravo (*Spain*)

J. Oldenburg (*Germany*)

Q&A

All

Please note: This symposium may include some results from research, clinical trials and scientific publications which may refer to medicines or indications not authorized in your country. Accordingly, any specific information provided on such medicines or indications is not intended as promotional material, but only as part of this educational symposium. Grifols complies with all federal and state reporting requirements regarding any value or expense associated with this event.

Martín Villar

Hemostasis Awards

GRIFOLS
SCIENTIFIC
AWARDS

The Martín Villar Hemostasis Awards aim to promote innovative ideas in the field of blood coagulation disorders (Hemophilia and von Willebrand disease).

The program will offer 2 awards of € 50,000 for Clinical Research and Basic Research.

Open May 22, 2018

Apply now!

Deadline March 1, 2019

For more information, please visit:
www.martinvillar-awards.com

GRIFOLS